Raquel Gallagher

Raquel Gallagher is a Biomedical Research Associate at Reboot Rx, where she supports clinical and policy initiatives to advance the use of repurposed generic drugs in cancer care. She joined Reboot Rx full-time after previously interning with the organization and focuses on translating scientific and regulatory evidence into practical strategies.

Raquel has contributed to several foundational initiatives, including co-authoring a 2024 policy publication examining regulatory pathways for nonprofit-led drug repurposing. She also supported the development of Reboot Rx’s first drug–cancer pair website, helping make complex clinical evidence clearer and more accessible for clinicians and researchers.

Prior to Reboot Rx, Raquel conducted research at Massachusetts General Hospital, studying COVID-19 vaccine responses in patients with multiple myeloma. She holds a Bachelor of Arts in Biological Sciences, with a concentration in Human Health and Disease, from Northwestern University.